ReviewFrontiers in oncology2025

Durvalumab consolidation therapy in patients with stage III small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis.

Hui Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.